Efficacy and safety of darolutamide plus androgen-deprivation therapy in Black patients with metastatic hormone-sensitive prostate cancer from the phase 3 ARANOTE trial Authors: Quoc-Dien Trinh, Daniel J. George, Neal Shore, Egils Vjaters, David Olmos, Andrea Juliana P. de Santana Gomes, Augusto Cesar de Andrade Mota, Natasha Littleton, Shankar Srinivasan, Frank Verholen, Kunhi Parambath Haresh, Fred Saad Published: 2026 ABSTRACT BackgroundThis analysis reports efficacy and safety data in the subgroup of Black patients from the ARANOTE phase 3 trial.MethodsPatients starting on androgen-deprivation therapy (ADT) were randomised 2:1 to receive darolutamide 600 mg twice daily or placebo. Of the total ARANOTE population (N = 669), 65 patients (10%; darolutamide, n = 41; placebo, n = 24) were Black.ResultsIn Black patients, darolutamide + ADT improved radiological progression-free survival (rPFS), reducing the risk of radiological progression or death by 49% vs ADT alone, consistent with the overall population.ConclusionsIn Black patients from ARANOTE, darolutamide was associated with improvement in rPFS. Incidence and mortality rates of prostate cancer are higher in Black patients compared with other racial groups [1], yet a recent multi-institutional analysis suggests Black patients with metastatic hormone-sensitive prostate cancer (mHSPC) have favourable outcomes with androgen-deprivation therapy (ADT)–based regimens [2]. ARANOTE (NCT04736199) was a global phase 3 trial, in which patients with mHSPC were randomly assigned to receive darolutamide or placebo, with concomitant ADT [3]. Darolutamide with ADT significantly reduced the risk of radiological progression or death by 46% (hazard ratio [HR] 0.54; 95% confidence interval [CI] 0.41–0.71; P < 0.0001) vs placebo plus ADT [3]. The incidence of treatment-emergent adverse events (TEAEs) was low and similar between groups, with fewer patients discontinuing darolutamide (6.1%) vs placebo (9.0%) due to TEAEs [3]. Here we report efficacy and safety of darolutamide plus ADT vs placebo plus ADT in Black patients from ARANOTE. In ARANOTE, patients starting on ADT therapy were randomised 2:1 to receive darolutamide 600 mg twice daily or placebo (full methodology has been published previously [3]). The primary endpoint was radiological progression-free survival (rPFS). Secondary endpoints included time to metastatic castration-resistant prostate cancer (mCRPC), time to prostate-specific antigen (PSA) progression, proportion of patients reaching PSA < 0.2 ng/mL at any time, time to initiation of subsequent anticancer therapy, time to pain progression, and safety. Medians and 95% CIs were computed using Kaplan–Meier estimates with HRs (95% CI) based on an unstratified Cox regression model. Statistical evaluations were performed using SAS software (version 9.4; SAS Institute Inc, Cary, NC). Patient demographics, baseline characteristics and TEAEs are reported descriptively. Of the total ARANOTE trial population (N = 669), 65 patients (10%; darolutamide, n = 41; placebo, n = 24) were self-reported Black, and located in Brazil (n = 58), South Africa (n = 6) and Australia (n = 1). Baseline characteristics were similar between treatment arms and generally consistent with the overall ARANOTE population, except that Black patients had higher median baseline PSA levels (99.6 vs 21.3 ng/mL) and a greater proportion had high-volume mHSPC (78.5% vs 70.6%). Median (range) age was 69 (48−84) vs 72 (50–89) years in the darolutamide vs placebo group. The number of patients with a Gleason score ≥ 8 at initial diagnosis was 26 (63.4%) vs 14 patients (58.3%) and with de novo disease was 29 (70.7%) vs 18 patients (75.0%) in the darolutamide vs placebo groups, respectively, in line with the overall ARANOTE population. Darolutamide reduced the risk of radiological progression or death by 49% in Black patients (HR 0.51, 95% CI 0.21–1.23), consistent with the overall population (Fig. 1a). Median follow-up was 24.9 months with darolutamide and 25.7 months with placebo. Median rPFS was not reached in either treatment group.Fig. 1Efficacy outcomes for Black patients in ARANOTE.a rPFS. *Primary analysis occurred after 222 events (darolutamide n = 128; placebo n = 94) in the overall population. Number of events in Black patients: darolutamide, n = 10/41 (24.4%); placebo, n = 10/24 (41.7%). HR and 95% CI are based on an unstratified Cox regression model. b Time to mCRPC. Number of events in Black patients: darolutamide, n = 14/41 (34.1%); placebo, n = 18/24 (75.0%). HR and 95% CI are based on an unstratified Cox regression model. c Time to PSA progression. Defined as the time from randomisation to first PSA progression (≥ 25% increased above the nadir value, confirmed by a second value ≥ 3 weeks later, and an increase in absolute PSA ≥ 2 ng/mL above nadir ≥ 12 weeks from baseline). Number of events in Black patients: darolutamide, n = 11/41 (26.8%); placebo, n = 14/24 (58.3%). HR and 95% CI are based on an unstratified Cox regression model. ADT androgen-deprivation therapy, CI confidence interval, HR hazard ratio, mCRPC metastatic castration-resistant prostate cancer, NR not reached, PSA prostate-specific antigen, rPFS radiological progression-free survival. Efficacy outcomes for Black patients in ARANOTE. a rPFS. *Primary analysis occurred after 222 events (darolutamide n = 128; placebo n = 94) in the overall population. Number of events in Black patients: darolutamide, n = 10/41 (24.4%); placebo, n = 10/24 (41.7%). HR and 95% CI are based on an unstratified Cox regression model. b Time to mCRPC. Number of events in Black patients: darolutamide, n = 14/41 (34.1%); placebo, n = 18/24 (75.0%). HR and 95% CI are based on an unstratified Cox regression model. c Time to PSA progression. Defined as the time from randomisation to first PSA progression (≥ 25% increased above the nadir value, confirmed by a second value ≥ 3 weeks later, and an increase in absolute PSA ≥ 2 ng/mL above nadir ≥ 12 weeks from baseline). Number of events in Black patients: darolutamide, n = 11/41 (26.8%); placebo, n = 14/24 (58.3%). HR and 95% CI are based on an unstratified Cox regression model. ADT androgen-deprivation therapy, CI confidence interval, HR hazard ratio, mCRPC metastatic castration-resistant prostate cancer, NR not reached, PSA prostate-specific antigen, rPFS radiological progression-free survival. The rPFS benefit of darolutamide was generally consistent across prespecified subgroups of Black patient subgroups of sufficient size and in which there were sufficient numbers of events, including those with baseline PSA values ≥ median of overall population (HR 0.46 [95% CI 0.17–1.27]), Eastern Cooperative Oncology Group Performance Status at baseline (0, HR 0.44 [95% CI 0.13–1.52] or ≥ 1, HR 0.56 [95% CI 0.16–1.95]), Gleason score ≥ 8 at initial diagnosis (HR 0.51 [95% CI 0.16–1.58]), high disease volume (HR 0.51 [95% CI 0.21–1.27]), absence of visceral metastasis (HR 0.47 [95% CI 0.17–1.31]) and absence of prior local therapy (HR 0.55 [95% CI 0.22–1.35]). The small sample size and limited number of events may contribute to wide CIs that cross 1.0. Darolutamide delayed time to mCRPC vs placebo in Black patients (HR 0.33 [95% CI 0.16–0.67]) (Fig. 1b). Black patients receiving darolutamide had a higher rate of PSA response < 0.2 ng/mL at any time vs placebo (59.5% vs 18.2%) and delayed time to PSA progression vs placebo (HR 0.33 [95% CI 0.15–0.73]) (Fig. 1c). In Black patients, darolutamide delayed time to initiation of subsequent anticancer therapy (HR 0.51 [95% CI 0.20–1.29]) and also delayed time to pain progression (HR 0.81 [95% CI 0.39–1.69]) vs placebo. With darolutamide, clinical benefits (assessed by comparing hazards of events) were generally similar between Black and non-Black patients for rPFS (HR 0.74 [95% CI 0.38–1.47]), time to mCRPC (HR 0.94 [95% CI 0.53–1.66]), and time to PSA progression (HR 1.27 [95% CI 0.67–2.39]). Incidences of TEAEs were similar between treatment groups in Black patients, consistent with the overall ARANOTE population. TEAEs leading to study-drug discontinuation were reported in 7.1% of patients taking darolutamide vs 4.3% of those on placebo in the Black population. TEAEs commonly associated with androgen receptor pathway inhibitors were generally similar between treatment groups in Black patients. The most common TEAEs were hypertension, vasodilatation/flushing, diabetes mellitus and hyperglycaemia. Black patients receiving darolutamide had lower rates of hypertension (21.4% vs 30.4%) and vasodilation/flushing (21.4% vs 26.1%) vs placebo. Incidence of fatigue was low (4.8% of patients receiving darolutamide vs 8.7% receiving placebo). The median duration of treatment in Black patients was 22.6 vs 19.5 months for darolutamide vs placebo (overall population: darolutamide, 24.2 months; placebo, 17.3 months). In summary, for the subgroup of Black patients from the ARANOTE trial, darolutamide was associated with an improvement in rPFS, and delayed time to mCRPC, time to PSA progression, time to initiation of subsequent anticancer therapy and time to pain progression compared with placebo, similar to the overall population. The rPFS benefit was consistent across all prespecified subgroups of Black patients. These findings are supported by the ARASENS Black patients subgroup study [4] in which patients with mHSPC were randomised 1:1 to darolutamide 600 mg or placebo twice daily in combination with ADT and docetaxel [4]. A total of 54 Black patients were included, and darolutamide was associated with improved survival and time to mCRPC, with favourable tolerability [4]. These results show a similar trend to the overall ARASENS study population. Efficacy data were limited by the small sample size and numbers of events. Nevertheless, the heterogeneity of the Black racial category enrolled should also be noted, suggesting applicability of our findings to Black patients beyond those included in our trial, the majority of whom were from Brazil. In addition, the proportion of Black patients in ARANOTE was higher than in similar studies of other androgen receptor inhibitors in mHSPC, including ARCHES (enzalutamide) and TITAN (apalutamide), in which 1–2% of patients were Black [5, 6]. These studies similarly reported improvements in survival, reduced risk of progression and safety/tolerability with androgen receptor inhibitors vs placebo [5, 6]. PSA response rates and time to PSA progression are notable in the Black population given higher PSA levels at baseline compared with the overall ARANOTE population, in which low baseline PSA and deep PSA response have each been linked to improved clinical outcomes [7]. Darolutamide exhibited a favourable safety profile in Black patients compared with placebo, which was generally consistent with the overall ARANOTE population between treatment groups. Together with the ARASENS subgroup analysis of Black patients, these studies confirm that the favourable efficacy and tolerability of darolutamide observed in the overall study populations are also seen in the Black patient subgroups in mHSPC. This is of particular importance given the higher risk and poorer prognosis of prostate cancer in the Black patient population.